NASDAQ:MDCX Medicus Pharma (MDCX) Stock Price, News & Analysis $0.33 -0.01 (-4.02%) Closing price 06/2/2026 04:00 PM EasternExtended Trading$0.33 0.00 (-0.99%) As of 06/2/2026 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock About Medicus Pharma Stock (NASDAQ:MDCX) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Medicus Pharma alerts:Sign Up Key Stats Today's Range$0.32▼$0.3450-Day Range$0.28▼$0.5152-Week Range$0.25▼$3.69Volume1.60 million shsAverage Volume2.81 million shsMarket Capitalization$18.94 millionP/E RatioN/ADividend YieldN/APrice Target$9.00Consensus RatingHold Company Overview Medicus Pharma, Inc., traded on the Nasdaq under the ticker MDCX, is a specialty pharmaceutical company focused on the development, acquisition and commercialization of prescription therapies. The company’s core business centers on oncology supportive care and critical care products, with its lead offering being Levoleucovorin injection, an FDA-approved agent designed to reduce toxicity and enhance efficacy of certain chemotherapeutic regimens in colorectal cancer. Headquartered in the United States, Medicus Pharma has built its portfolio through strategic licensing and acquisition of sterile injectable and oral therapies. Its research and development efforts are centered on expanding a pipeline that includes additional oncology supportive care candidates as well as treatments aimed at acute neurological and critical conditions. The company partners with established contract manufacturers and distributors to facilitate efficient production and market access. Medicus Pharma primarily serves the U.S. market through a network of specialty pharmacies and hospital systems and is evaluating opportunities for international distribution. Led by a management team with experience in specialty pharmaceuticals, regulatory affairs and commercial operations, the company remains focused on advancing its pipeline and delivering targeted support therapies for patients undergoing cancer treatment and acute care interventions.AI Generated. May Contain Errors. Read More Medicus Pharma Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks52nd Percentile Overall ScoreMDCX MarketRank™: Medicus Pharma scored higher than 52% of companies evaluated by MarketBeat, and ranked 553rd out of 869 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.7 / 5Analyst RatingHold Consensus RatingMedicus Pharma has received a consensus rating of Hold. The company's average rating score is 2.25, and is based on no strong buy ratings, 2 buy ratings, 1 hold rating, and 1 sell rating.Upside PotentialMedicus Pharma has a consensus price target of $9.00, representing about 2,592.2% upside from its current price of $0.33.Amount of Analyst CoverageMedicus Pharma has only been the subject of 3 research reports in the past 90 days.Read more about Medicus Pharma's stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for Medicus Pharma are expected to grow in the coming year, from ($0.51) to ($0.39) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Medicus Pharma is -0.12, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Medicus Pharma is -0.12, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Read more about Medicus Pharma's valuation and earnings. Short Interest3.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted4.21% of the float of Medicus Pharma has been sold short.Short Interest Ratio / Days to CoverMedicus Pharma has a short interest ratio ("days to cover") of 0.83, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Medicus Pharma has recently increased by 24.51%, indicating that investor sentiment is decreasing significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldMedicus Pharma does not currently pay a dividend.Dividend GrowthMedicus Pharma does not have a long track record of dividend growth. News and Social Media2.4 / 5News Sentiment0.83 News SentimentMedicus Pharma has a news sentiment score of 0.83. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.News Coverage This WeekMarketBeat has tracked 5 news articles for Medicus Pharma this week, compared to 5 articles on an average week.Search InterestOnly 25 people have searched for MDCX on MarketBeat in the last 30 days. This is a decrease of -38% compared to the previous 30 days.MarketBeat Follows28 people have added Medicus Pharma to their MarketBeat watchlist in the last 30 days. This is an increase of 100% compared to the previous 30 days. Company Ownership0.3 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Medicus Pharma insiders have not sold or bought any company stock.Percentage Held by Insiders8.10% of the stock of Medicus Pharma is held by insiders.Percentage Held by InstitutionsMedicus Pharma has minimal institutional ownership at this time.Read more about Medicus Pharma's insider trading history. Receive MDCX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Medicus Pharma and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. MDCX Stock News HeadlinesMedicus Pharma Ltd: Medicus Pharma Announces $22 Million Non-Dilutive FinancingMay 28, 2026 | finanznachrichten.deMedicus Pharma secures up to $22M in non-dilutive financing facilityMay 28, 2026 | proactiveinvestors.comElon Musk’s $1 Quadrillion AI IPO$1 quadrillion would be enough to send a $2.8 million check to every man, woman, and child in America. That is the scale of what analysts are calling the biggest AI IPO in history.And right now, you can claim a stake before the company goes public, starting with just $500.Elon Musk is predicting this investment could climb 1,000x from here. Early access is available today. | Brownstone Research (Ad)Medicus Pharma Announces $22 Million Non-Dilutive FinancingMay 28, 2026 | globenewswire.comMedicus Pharma Secures Financing Amid Nasdaq Compliance PressureMay 27, 2026 | tipranks.comAnalysts Offer Predictions for Medicus Pharma Q2 EarningsMay 25, 2026 | americanbankingnews.comMedicus Pharma Ltd. (MDCXW) Reports FDA Progress and Expands 2026 Clinical OutlookMay 19, 2026 | insidermonkey.comMedicus Pharma sees catalyst-rich year ahead as SkinJect and Teverelix progressMay 15, 2026 | proactiveinvestors.comSee More Headlines MDCX Stock Analysis - Frequently Asked Questions How have MDCX shares performed this year? Medicus Pharma's stock was trading at $1.53 at the start of the year. Since then, MDCX stock has decreased by 78.2% and is now trading at $0.3343. How were Medicus Pharma's earnings last quarter? Medicus Pharma Ltd (NASDAQ:MDCX) posted its quarterly earnings data on Thursday, May, 14th. The company reported ($0.31) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.18) by $0.13. When did Medicus Pharma IPO? Medicus Pharma (MDCX) raised $4 million in an initial public offering on Thursday, November 14th 2024. The company issued 1,000,000 shares at $4.13 per share. Maxim Group LLC served as the underwriter for the IPO and Brookline Capital Markets was co-manager. Who are Medicus Pharma's major shareholders? Medicus Pharma's top institutional investors include Private Advisor Group LLC (0.61%). View institutional ownership trends. How do I buy shares of Medicus Pharma? Shares of MDCX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Company Calendar Last Earnings5/14/2026Today6/02/2026Next Earnings (Estimated)8/10/2026Fiscal Year End12/31/2026Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED - BIOMED/GENE Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:MDCX Previous SymbolNASDAQ:MDCX CIK1997296 Webwww.medicuspharma.com Phone732-300-3046FaxN/AEmployeesN/AYear FoundedN/APrice Target and Rating Average Price Target for Medicus Pharma$9.00 High Price Target$9.00 Low Price Target$9.00 Potential Upside/Downside+2,592.2%Consensus RatingHold Rating Score (0-4)2.25 Research Coverage4 Analysts Profitability EPS (Trailing Twelve Months)($2.68) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$35.46 million Net MarginsN/A Pretax MarginN/A Return on Equity-3,137.84% Return on Assets-311.33% Debt Debt-to-Equity RatioN/A Current Ratio1.22 Quick Ratio1.22 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book ValueN/A Price / BookN/AMiscellaneous Outstanding Shares56,660,000Free Float52,069,000Market Cap$18.94 million OptionableN/A Beta0.14 7 Stocks to Buy And Hold ForeverClick the link to see MarketBeat's list of seven stocks and why their long-term outlooks are very promising. Get This Free Report This page (NASDAQ:MDCX) was last updated on 6/3/2026 by MarketBeat.com Staff. From Our PartnersThe 1934 playbookIn 1934, a legal government maneuver transferred billions in wealth overnight. Most Americans never saw it com...American Alternative | Sponsored$30 stock to buy before Starlink goes public (WATCH NOW!)In the next 3 minutes… James Altucher – legendary investor and venture capitalist… And someone who’s kno...Paradigm Press | SponsoredTrump's gold order: the announcement they won't put on the front pageOn August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no deb...Reagan Gold Group | SponsoredYour book attachedBill Poulos is giving away his 'Safe Trade Options Formula' book for free - but only for a limited time throug...Profits Run | SponsoredJune 12: $100 Turns Into $100,000?The SpaceX IPO is scheduled for June 12, and former tech executive Jeff Brown - who identified Bitcoin, Tesla,...Brownstone Research | SponsoredMy feud with Zohran MamdaniEmmy-winning analyst releases his next big story Whitney Tilson shocked the nation on 60 Minutes when he ac...Stansberry Research | SponsoredSpaceX just filed. The clock is ticking.Reuters reports Elon Musk filed secretly. Barron's says it's being finalized behind closed doors. CNBC just re...The Oxford Club | SponsoredSpaceX will mint billionaires. You won't be one of them.By the time a company goes public, 95% of profits have already been made. Insiders bought SpaceX at $20 billio...Behind the Markets | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Medicus Pharma Ltd Please log in to your account or sign up in order to add this asset to your watchlist. Share Medicus Pharma With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free MDCX Stock Alerts